AT2R agonist, compound 21, is Reno-protective against type 1 diabetic nephropathy

Hypertension

Volumn 65, Issue 5, 2015, Pages 1073-1081

  Koulis, Christine ^a   Chow, Bryna S M ^a   Mckelvey, Maria ^a   Steckelings, Ulrike M ^c   Unger, Thomas ^d   Thallas Bonke, Vicki ^a   Thomas, Merlin C ^a,b   Cooper, Mark E ^a,b   Jandeleit Dahm, Karin A ^a,b   Allen, Terri J ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

angiotensin II; AT2 receptor; compound 21; diabetic nephropathy; kidney

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN RECEPTOR AGONIST; COLLAGEN TYPE 1; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; CYSTATIN C; GELATINASE A; HORMONE RECEPTOR STIMULATING AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANGIOTENSIN 2 RECEPTOR; N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1-YLMETHYLPHENYL)-5-ISOBUTYLTHIOPHENE-2-SULFONAMIDE; SULFONAMIDE; THIOPHENE DERIVATIVE;

ALBUMINURIA; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; FIBROSIS; GENE EXPRESSION; GLOMERULOSCLEROSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY HYPERTROPHY; KIDNEY INJURY; MESANGIUM CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENAL PROTECTION; UPREGULATION; AGONISTS; ANIMAL; CELL CULTURE; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PATHOLOGY;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; IMMUNOHISTOCHEMISTRY; MESANGIAL CELLS; MICE; OXIDATIVE STRESS; RECEPTOR, ANGIOTENSIN, TYPE 2; SULFONAMIDES; THIOPHENES;

EID: 84930989439     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05204     Document Type: Article

References (44)

1. Darby IA, Hewitson TD. Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol. 2007; 257: 143-179. doi: 10.1016/ S0074-7696(07)57004-X.
2. Singh KP, Gerard HC, Hudson AP, Boros DL. Dynamics of collagen, MMP and TIMP gene expression during the granulomatous, fibrotic process induced by Schistosoma mansoni eggs. Ann Trop Med Parasitol. 2004; 98: 581-593. doi: 10.1179/000349804225021316
3. Rincon-Choles H, Kasinath BS, Gorin Y, Abboud HE. Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy. Kidney Int Suppl. 2002; S8-11
4. Vivian EM, Rubinstein GB. Pharmacologic management of diabetic nephropathy. Clin Ther. 2002; 24: 1741-1756, discussion 1719
5. Appel G. Detecting and controlling diabetic nephropathy: what do we know?. Cleve Clin J Med. 2013; 80: 209-217. doi: 10.3949/ ccjm.80gr.12006
6. Panzer U, Thaiss F, Zahner G, Barth P, Reszka M, Reinking RR, Wolf G, Helmchen U, Stahl RA. Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis. Kidney Int. 2001; 59: 1762-1769. doi: 10.1046/j.1523-1755.2001.0590051762.x.
7. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Kinoshita M. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol. 2000; 35: 714-721
8. Wolf G, Ziyadeh FN, Zahner G, Stahl RA. Angiotensin II-stimulated expression of transforming growth factor beta in renal proximal tubular cells: attenuation after stable transfection with the c-mas oncogene. Kidney Int. 1995; 48: 1818-1827
9. Liu BC, Sun J, Chen Q, Ma KL, Ruan XZ, Phillips AO. Role of connective tissue growth factor in mediating hypertrophy of human proximal tubular cells induced by angiotensin II. Am J Nephrol. 2003; 23: 429-437. doi: 74534
10. Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol. 2007; 18: 2439-2446. doi: 10.1681/ ASN.2007020149
11. Rüster C, Wolf G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol. 2011; 22: 1189-1199. doi: 10.1681/ ASN.2010040384
12. Arima S, Ito S. Angiotensin II type 2 receptors in the kidney: evidence for endothelial-cell-mediated renal vasodilatation. Nephrol Dial Transplant. 2000; 15: 448-451
13. Johren O, Dendorfer A, Dominiak P. Cardiovascular and renal function of angiotensin II type-2 receptors. Cardiovasc Res. 2004; 62: 460-467
14. Chang SY, Chen YW, Chenier I, Tran Sle M, Zhang SL. Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2. Exp Diabetes Res. 2011; 2011: 521076. doi: 10.1155/2011/521076
15. Ma J, Nishimura H, Fogo A, Kon V, Inagami T, Ichikawa I. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int. 1998; 53: 937-944. doi: 10.1111/j.1523-1755.1998.00893.x.
16. Morrissey JJ, Klahr S. Effect of AT2 receptor blockade on the pathogenesis of renal fibrosis. Am J Physiol. 1999; 276(1 Pt 2): F39-F45
17. AbdAlla S, Lother H, Abdel-Tawab AM, Quitterer U. The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem. 2001; 276: 39721-39726. doi: 10.1074/jbc.M105253200
18. Shao C, Yu L, Gao L. Activation of angiotensin type 2 receptors partially ameliorates streptozotocin-induced diabetes in male rats by islet protection. Endocrinology. 2014; 155: 793-804. doi: 10.1210/ en.2013-1601
19. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 1995; 25: 1111-1115
20. Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R, Burns WC, Forbes JM, Calkin AC, Cooper ME, Jandeleit-Dahm KA. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol. 2004; 15: 2125-2138. doi: 10.1097/01.ASN.0000133025.23732.46
21. Watson AM, Li J, Schumacher C, De Gasparo M, Feng B, Thomas MC, Allen TJ, Cooper ME, Jandeleit-Dahm KA. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia. 2010; 53: 192-203. doi: 10.1007/s00125-009-1540-3
22. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest. 2001; 108: 1853-1863. doi: 10.1172/JCI11951
23. Basile DP, Fredrich K, Weihrauch D, Hattan N, Chilian WM. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol. 2004; 286: F893-F902. doi: 10.1152/ ajprenal.00328.2003
24. Catania JM, Chen G, Parrish AR. Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol. 2007; 292: F905-F911. doi: 10.1152/ajprenal.00421.2006
25. Bolbrinker J, Markovic S, Wehland M, Melenhorst WB, Van Goor H, Kreutz R. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension. J Pharmacol Exp Ther. 2006; 316: 8-16. doi: 10.1124/ jpet.105.093112
26. Uchio-Yamada K, Manabe N, Goto Y, Anann S, Yamamoto Y, Takano K, Ogura A, Matsuda J. Decreased expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in the kidneys of hereditary nephrotic (ICGN) mice. J Vet Med Sci. 2005; 67: 35-41
27. Takamiya Y, Fukami K, Yamagishi S, Kaida Y, Nakayama Y, Obara N, Iwatani R, Ando R, Koike K, Matsui T, Nishino Y, Ueda S, Cooper ME, Okuda S. Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice. Nephrol Dial Transplant. 2013; 28: 55-62. doi: 10.1093/ndt/gfs387
28. Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag. 2008; 4: 575-596
29. Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension. 2005; 45: 840-844. doi: 10.1161/01.HYP.0000159192.93968.8f.
30. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008; 120: 292-316. doi: 10.1016/j.pharmthera.2008.08.009
31. Ali Q, Sabuhi R, Hussain T. High glucose up-regulates angiotensin II subtype 2 receptors via interferon regulatory factor-1 in proximal tubule epithelial cells. Mol Cell Biochem. 2010; 344: 65-71. doi: 10.1007/ s11010-010-0529-z
32. Dhande I, Ali Q, Hussain T. Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats. Hypertension. 2013; 61: 1218-1226. doi: 10.1161/ HYPERTENSIONAHA.111.00422
33. McMullen JR, Gibson KJ, Lumbers ER, Burrell JH. Selective down-regulation of AT2 receptors in uterine arteries from pregnant ewes given 24-h intravenous infusions of angiotensin II. Regul Pept. 2001; 99: 119-129
34. Pulgar VM, Yamashiro H, Rose JC, Moore LG. Role of the AT2 receptor in modulating the angiotensin II contractile response of the uterine artery at mid-gestation. J Renin Angiotensin Aldosterone Syst. 2011; 12: 176-183. doi: 10.1177/1470320310397406
35. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors: cardiovascular hope or hype?. Br J Pharmacol. 2003; 140: 809-824. doi: 10.1038/sj.bjp.0705448
36. Castoldi G, di Gioia CR, Bombardi C, Maestroni S, Carletti R, Steckelings UM, Dahlöf B, Unger T, Zerbini G, Stella A. Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. Am J Physiol Renal Physiol. 2014; 307: F1123-F1131. doi: 10.1152/ajprenal.00247.2014
37. Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004; 47: 5995-6008. doi: 10.1021/jm049715t
38. Matavelli LC, Huang J, Siragy HM. Angiotensin AT2 receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension. 2011; 57: 308-313. doi: 10.1161/ HYPERTENSIONAHA.110.164202
39. Chow BS, Kocan M, Bosnyak S, Sarwar M, Wigg B, Jones ES, Widdop RE, Summers RJ, Bathgate RA, Hewitson TD, Samuel CS. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis. Kidney Int. 2014; 86: 75-85. doi: 10.1038/ki.2013.518
40. Anguiano-Robledo L, Reyes-Melchor PA, Bobadilla-Lugo RA, Pérez- Alvarez VM, López-Sánchez P. Renal angiotensin-II receptors expression changes in a model of preeclampsia. Hypertens Pregnancy. 2007; 26: 151-161. doi: 10.1080/10641950701252827
41. Yang J, Chen C, Ren H, Han Y, He D, Zhou L, Hopfer U, Jose PA, Zeng C. Angiotensin II AT(2) receptor decreases AT(1) receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats. J Hypertens. 2012; 30: 1176-1184
42. N Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA. 1995; 92: 10663-10667
43. Xu ZG, Lanting L, Vaziri ND, Li Z, Sepassi L, Rodriguez-Iturbe B, Natarajan R. Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade. Circulation. 2005; 111: 1962-1969. doi: 10.1161/01.CIR.0000161831.07637.63
44. Siragy HM. The angiotensin II type 2 receptor and the kidney. J Renin Angiotensin Aldosterone Syst. 2010; 11: 33-36. doi: 10.1177/1470320309347786